scholarly journals Clinical Practice Guideline: Ménière’s Disease

2020 ◽  
Vol 162 (2_suppl) ◽  
pp. S1-S55 ◽  
Author(s):  
Gregory J. Basura ◽  
Meredith E. Adams ◽  
Ashkan Monfared ◽  
Seth R. Schwartz ◽  
Patrick J. Antonelli ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Clinical Practice ◽  
Sensorineural Hearing Loss ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Meniere’S Disease ◽  
Sensorineural Hearing ◽  
Ménière’S Disease ◽  
Ménière's Disease

Objective Ménière’s disease (MD) is a clinical condition defined by spontaneous vertigo attacks (each lasting 20 minutes to 12 hours) with documented low- to midfrequency sensorineural hearing loss in the affected ear before, during, or after one of the episodes of vertigo. It also presents with fluctuating aural symptoms (hearing loss, tinnitus, or ear fullness) in the affected ear. The underlying etiology of MD is not completely clear, yet it has been associated with inner ear fluid (endolymph) volume increases, culminating in episodic ear symptoms (vertigo, fluctuating hearing loss, tinnitus, and aural fullness). Physical examination findings are often unremarkable, and audiometric testing may or may not show low- to midfrequency sensorineural hearing loss. Conventional imaging, if performed, is also typically normal. The goals of MD treatment are to prevent or reduce vertigo severity and frequency; relieve or prevent hearing loss, tinnitus, and aural fullness; and improve quality of life. Treatment approaches to MD are many and typically include modifications of lifestyle factors (eg, diet) and medical, surgical, or a combination of therapies. Purpose The primary purpose of this clinical practice guideline is to improve the quality of the diagnostic workup and treatment outcomes of MD. To achieve this purpose, the goals of this guideline are to use the best available published scientific and/or clinical evidence to enhance diagnostic accuracy and appropriate therapeutic interventions (medical and surgical) while reducing unindicated diagnostic testing and/or imaging.

scholarly journals Clinical Practice Guideline: Ménière’s Disease Executive Summary

2020 ◽  
Vol 162 (4) ◽  
pp. 415-434 ◽  
Author(s):  
Gregory J. Basura ◽  
Meredith E. Adams ◽  
Ashkan Monfared ◽  
Seth R. Schwartz ◽  
Patrick J. Antonelli ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Clinical Practice ◽  
Sensorineural Hearing Loss ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Meniere’S Disease ◽  
Sensorineural Hearing ◽  
Ménière’S Disease ◽  
Ménière's Disease

Objective Ménière’s disease (MD) is a clinical condition defined by spontaneous vertigo attacks (each lasting 20 minutes to 12 hours) with documented low- to midfrequency sensorineural hearing loss in the affected ear before, during, or after one of the episodes of vertigo. It also presents with fluctuating aural symptoms (hearing loss, tinnitus, or ear fullness) in the affected ear. The underlying etiology of MD is not completely clear, yet it has been associated with inner ear fluid volume increases, culminating in episodic ear symptoms (vertigo, fluctuating hearing loss, tinnitus, and aural fullness). Physical examination findings are often unremarkable, and audiometric testing may or may not show low- to midfrequency sensorineural hearing loss. Imaging, if performed, is also typically normal. The goals of MD treatment are to prevent or reduce vertigo severity and frequency; relieve or prevent hearing loss, tinnitus, and aural fullness; and improve quality of life. Treatment approaches to MD are many, and approaches typically include modifications of lifestyle factors (eg, diet) and medical, surgical, or a combination of therapies. Purpose The primary purpose of this clinical practice guideline is to improve the quality of the diagnostic workup and treatment outcomes of MD. To achieve this purpose, the goals of this guideline are to use the best available published scientific and/or clinical evidence to enhance diagnostic accuracy and appropriate therapeutic interventions (medical and surgical) while reducing unindicated diagnostic testing and/or imaging.

Risk of Progressive Sensorineural Hearing Loss and Meniere's Disease after Breast Implantation

1998 ◽  
Vol 118 (6) ◽  
pp. 747-750 ◽  
Author(s):  
DAVID WOOJIN KIM ◽  
JEFFREY P. HARRIS
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Breast Implants ◽  
Meniere’S Disease ◽  
Sensorineural Hearing ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Silicone Breast Implants ◽  
Ménière's Disease

OBJECTIVE: The association of various immunologic abnormalities with the presence of silicone breast implants in women has been described. In addition, some studies report a correlation between autoimmune disorders and silicone breast implants, whereas other studies indicate no difference in the incidence of disease between women with silicone breast implants and control groups. Until recently, no reports had attempted to identify an association between silicone breast implants and hearing impairment. A recent study suggested a possible correlation between prior silicone breast implants and the development of various forms of hearing loss. This study tried to determine whether such a correlation could be duplicated. METHODS: To determine whether such a correlation could be established, we studied 119 female patients with either Meniere's disease or progressive sensorineural hearing loss and 100 age-matched healthy controls. Subjects completed questionnaires that provided various types of information, including the presence or absence of previous silicone breast implants. Serum from all 119 patients with Meniere's disease and progressive sensorineural hearing loss had been subjected to previous Western blot testing for reactivity to a 68 kD protein associated with certain forms of autoimmune hearing loss. RESULTS: Results indicated no significant difference in frequency of prior silicone breast implants among the patients with Meniere's disease, patients with sensorineural hearing loss, or controls. The presence or absence of the 68 kD protein also was not significantly relevant to the frequency of silicone breast implants. CONCLUSIONS: Our data did not show evidence of a significant relationship between the presence of silicone breast implants and later development of Meniere's disease, progressive sensorineural hearing loss, or positive 68 kD serum. (Otolaryngol Head Neck Surg 1998;118:747-50.)

scholarly journals Concept and Management of Meniere’s Disease in Unani Medicine-A Review

2021 ◽  
Vol 11 (5) ◽  
pp. 174-177
Author(s):  
Abdul Nasir ◽  
Minhaj Ahmad ◽  
Zehra Zaidi ◽  
SM Arif Zaidi
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Meniere’S Disease ◽  
Sensorineural Hearing ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Unani Medicine ◽  
Ménière's Disease

Meniere’s disease, also called endolymphatic hydrops, is a disorder of the inner ear where the endolymphatic system is distended due to endolymph. It is characterized by vertigo, Tinnitus, sensorineural hearing loss and aural fullness. The main pathology in Meniere’s disease is distention of endolymphatic system due to increased volume of endolymph. This can result either from increased production of endolymph or its faulty absorption or both. The description of hypothyroidism as a disease is not directly found in Unani texts. However, the signs and symptoms of meniere’s disease such as Dawar (vertigo), Taneen (tinnitus), Hissi Asabi Bahrapan (sensorineural hearing loss), Seqal-e-Uzn (aural fullness) mentioned in unani medicine associated with clinical manifestation in the context of Su-e-Mizaj Barid Maddi (derangement in cold temperament) as a result of an excess production endolymph (Kasrate Ifraz-e-Androon lymph) or defective absorption of endolymph (Nuqse Jazb-e- Androon lymph) in abnormal phlegm in the internal ear. On the basis of this fact, an attempt has been herewith made to understand the disease and its management through Unani Medicine. Keywords: Meniere’s disease, Vertigo, Tinnitus, Taneen, Deafness

scholarly journals Simultaneous Labyrinthectomy and Cochlear Implantation for Patients with Single-Sided Ménière’s Disease and Profound Sensorineural Hearing Loss

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
G. Doobe ◽  
A. Ernst ◽  
R. Ramalingam ◽  
P. Mittmann ◽  
I. Todt
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Cochlear Implantation ◽  
Meniere’S Disease ◽  
Sensorineural Hearing ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Ménière's Disease

Objective.To investigate the treatment outcome of a simultaneous labyrinthectomy and cochlear implantation in patients with single-sided Ménière’s disease and profound sensorineural hearing loss.Study Design.Prospective study.Method.Five patients with single-sided Ménière’s disease with active vertigo and functional deafness were included. In all cases, simultaneous cochlear implantation combined with labyrinthectomy surgery was performed. The outcome has been evaluated by the Dizziness Handicap Inventory (DHI) and speech recognition.Results.The combined labyrinthectomy and cochlear implantation led in all patients to a highly significant reduction of dizziness up to arestitutio ad integrum. After activation of the cochlear implant and rehabilitation, a mean monosyllabic speech understanding of 69% at 65 dB was observed.Conclusion.For patients with single-sided Ménière’s disease and profound sensorineural hearing loss the simultaneous labyrinthectomy and cochlear implantation are efficient method for the treatment of vertigo as well as the rehabilitation of the auditory system.

Sign in / Sign up

Export Citation Format

Share Document